Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313352 · ClinicalTrials.gov registry record
Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 110
- Enrollment target
NCT00313352: Completed study, sponsored by Emory University.
NCT00313352 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313352 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
The purpose of this chart review study is to examine the effects of beta -adrenergic blocking agents on systemic ventricular dimensions, systemic atrioventricular valve function and exercise tolerance in patients with transposition of the great arteries (TGA) and systemic ventricular dysfunction.
Primary Outcome
beta blockers improved functional class in patient's with transposition and systemic right ventricles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 1997-01 |
| Est. Completion | 2007-03 |
What the finished NCT00313352 record still lists
NCT00313352 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00313352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313352 about?
NCT00313352 is a clinical study titled "Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function". The purpose of this chart review study is to examine the effects of beta -adrenergic blocking agents on systemic ventricular dimensions, systemic atrioventricular valve function and exercise tolerance in patients with transposition of the great arteries (TGA) and systemic ventricular dysfunction.
What is the current status of trial NCT00313352?
This trial is currently completed. The enrollment target is 110 participants. The study started on 1997-01. Estimated completion is 2007-03.
Who is sponsoring clinical trial NCT00313352?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia